文献速递间质性肺疾病

GLPG1205治疗特发性肺纤维化:2期随机安慰剂对照试验

GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.
PubMed 文献 · Eur Respir J · 2023-03-02

PINTA试验为2期随机双盲安慰剂对照概念验证研究,68例IPF患者按2:1随机接受GLPG1205 100mg每日一次或安慰剂治疗26周。主要终点FVC变化两组间无显著差异(差值42.33mL,95%CI -81.84-166.5,p=0.50),GLPG1205安全性和耐受性劣于安慰剂。

要点

  • GLPG1205 100mg每日一次治疗26周未显著减缓IPF患者FVC下降。
  • GLPG1205组严重和重度治疗中出现的不良事件及停药比例高于安慰剂。
  • 该研究未针对统计学显著性进行效力计算。

核心结论

  • GLPG1205治疗未较安慰剂显著改善IPF患者FVC下降。
  • GLPG1205的安全性和耐受性劣于安慰剂。

研究设计与样本

  • PINTA为2期随机双盲安慰剂对照概念验证试验(NCT03725852)。
  • IPF患者按2:1随机接受口服GLPG1205 100mg每日一次或安慰剂治疗26周。
  • 患者分层接受GLPG1205单药或联合局部标准治疗(尼达尼布或吡非尼酮)。
  • 共68例患者接受研究药物。
  • 研究未针对统计学显著性进行效力计算。

主要发现

  • 第26周FVC较基线最小二乘均值变化:GLPG1205组-33.68mL(95%CI -112.0-44.68),安慰剂组-76.00mL(95%CI -170.7-18.71)。
  • 最小二乘均值差值42.33mL(95%CI -81.84-166.5),p=0.50。
  • 影像学肺容积变化:全肺GLPG1205组-58.30mL vs 安慰剂组-262.72mL;下叶-33.68mL vs -135.48mL。
  • GLPG1205组严重和重度治疗中出现的不良事件及治疗中出现的停药比例高于安慰剂组,在联合尼达尼布时最明显。

关键数值与推荐

  • 主要终点为FVC较基线变化。
  • 其他终点包括安全性和耐受性以及影像学(高分辨率CT)测量的肺容积。

临床怎么用

  • GLPG1205未显示减缓IPF患者FVC下降的疗效,且安全性和耐受性较差。

局限性

  • 研究未针对统计学显著性进行效力计算。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GLPG1205 is a selective functional antagonist of G-protein-coupled receptor 84, which plays an important role in fibrotic processes. This study assessed the efficacy, safety and tolerability of GLPG1205 for treatment of idiopathic pulmonary fibrosis (IPF). METHODS: PINTA (ClinicalTrials.gov: NCT03725852) was a phase 2, randomised, double-blind, placebo-controlled, proof-of-concept trial. Patients with IPF were randomised 2:1 to once-daily oral GLPG1205 100 mg or placebo for 26 weeks and stratified to receive GLPG1205 alone or with local standard of care (nintedanib or pirfenidone). The primary end-point was change from baseline in forced vital capacity (FVC); other end-points were safety and tolerability, and lung volumes measured by imaging (high-resolution computed tomography). The study was not powered for statistical significance. RESULTS: In total, 68 patients received study medication. Least squares mean change from baseline in FVC at week 26 was -33.68 (95% CI -112.0-44.68) mL with GLPG1205 and -76.00 (95% CI -170.7-18.71) mL with placebo (least squares mean difference 42.33 (95% CI -81.84-166.5) mL; p=0.50). Lung volumes by imaging declined -58.30 versus -262.72 mL (whole lung) and -33.68 versus -135.48 mL (lower lobes) with GLPG1205 versus placebo, respectively. Treatment with GLPG1205 versus placebo resulted in higher proportions of serious and severe treatment-emergent adverse events and treatment-emergent discontinuations, most apparent with nintedanib. CONCLUSIONS: Treatment with GLPG1205 did not result in a significant difference in FVC decline versus placebo. GLPG1205 demonstrated a poorer safety and tolerability profile than placebo.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Strambu IR, Seemayer CA, Fagard LMA, et al. GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial. Eur Respir J. 2023. PMID: 36328358. doi:10.1183/13993003.01794-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。